GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » 10-Year Sortino Ratio

Hualan Biological Engineering (SZSE:002007) 10-Year Sortino Ratio : 0.18 (As of Jul. 24, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering 10-Year Sortino Ratio?

The 10-Year Sortino Ratio measures the additional return that an investor receives per unit of the downside risk over the past ten years. As of today (2025-07-24), Hualan Biological Engineering's 10-Year Sortino Ratio is 0.18.


Competitive Comparison of Hualan Biological Engineering's 10-Year Sortino Ratio

For the Biotechnology subindustry, Hualan Biological Engineering's 10-Year Sortino Ratio, along with its competitors' market caps and 10-Year Sortino Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's 10-Year Sortino Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's 10-Year Sortino Ratio distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's 10-Year Sortino Ratio falls into.


;
;

Hualan Biological Engineering 10-Year Sortino Ratio Calculation

The 10-Year Sortino Ratio measures the risk-adjusted return of an investment asset or portfolio in the last ten year, focusing specifically on downside risk rather than total risk. A stock / portfolio's 10-Year Sortino Ratio can be calculated by dividing the difference between the ten-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the downside risks over the past ten year.

A downside risk is a potential loss from the asset or investment. The Downside risk here is measured by the downside deviation, which is the standard deviation of negative returns.


Hualan Biological Engineering  (SZSE:002007) 10-Year Sortino Ratio Explanation

The 10-Year Sortino Ratio inidicates the risk-adjusted return of an investment over the past ten year. It is calculated as the annualized result of the average ten-year monthly excess returns divided by the standard deviation of negative returns in the ten-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

Differnt from the Sharpe Ratio that penalizes both upside and downside volatility equally, the Sortino Ratio penalizes only those returns falling below a user-specified target or required rate of return. The expected returns here is set to the risk-free rate as well.


Hualan Biological Engineering 10-Year Sortino Ratio Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's 10-Year Sortino Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
Chen Zheng Yue Executives
Fan Bei Directors, executives
Pan Ruo Wen Executives
Xie Jun Min Directors, executives
An Wen Qi Executives
An Kang Directors, executives
Ma Xiao Wei Executives
Zhang Bao Xian Executives
An Wen Jue Director
Liu Jun Executives
Wang Qi Ping Directors, executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors

Hualan Biological Engineering Headlines

No Headlines